BioVie Inc. Files 8-K: Material Agreement, Equity Sales

TL;DR

BioVie Inc. (BIVI) filed an 8-K detailing a material agreement and equity sales.

AI Summary

BioVie Inc. filed an 8-K on October 24, 2024, reporting on events as of October 23, 2024. The filing indicates a material definitive agreement, unregistered sales of equity securities, and Regulation FD disclosures. It also includes financial statements and exhibits, with the company previously known as NanoAntibiotics, Inc.

Why It Matters

This 8-K filing by BioVie Inc. signals significant corporate activity, including a material definitive agreement and unregistered equity sales, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financing needs or dilution concerns.

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• NANOANTIBIOTICS, INC. (company) — Former Company Name
• October 23, 2024 (date) — Date of earliest event reported
• October 24, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke
• $2.25 — blic offering price to the Investors of $2.25 per share (the " Share Offering Price "
• $2.12 — of Common Stock at an exercise price of $2.12 per share. Each Warrant will be exercis
• $100 — ing, for an aggregate purchase price of $100.00, at an exercise price of $2.8125 per
• $2.8125 — ice of $100.00, at an exercise price of $2.8125 per share, which is equal to 125% of th
• $6,000,750 b — fering are expected to be approximately $6,000,750 before deducting placement agent fees and

Filing Documents

• bivi-20241023_8k.htm (8-K) — 36KB
• bivi-20241023_8kex4z1.htm (EX-4.1) — 114KB
• bivi-20241023_8kex5z1.htm (EX-5.1) — 16KB
• bivi-20241023_8kex10z1.htm (EX-10.1) — 381KB
• bivi-20241023_8kex99z1.htm (EX-99.1) — 10KB
• image_01.jpg (GRAPHIC) — 22KB
• image_02.jpg (GRAPHIC) — 15KB
• 0001520138-24-000379.txt ( ) — 918KB
• bivi-20241023.xsd (EX-101.SCH) — 3KB
• bivi-20241023_lab.xml (EX-101.LAB) — 33KB
• bivi-20241023_pre.xml (EX-101.PRE) — 24KB
• bivi-20241023_8k_htm.xml (XML) — 3KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement On October 23, 2024, BioVie Inc. (the " Company ") entered into a placement agent agreement (the " Agreement ") with ThinkEquity LLC, as the placement agent (the " Placement Agent "), in connection with the issuance and sale (the " Offering ") directly to various investors (the " Investors ") of up to 2,667,000 shares (the " Shares ") of the Company's Class A common stock, par value $0.0001 per share (the " Common Stock "), at a public offering price to the Investors of $2.25 per share (the " Share Offering Price "). In a concurrent private placement (the " Private Placement "), the Company agreed, pursuant to the Agreement, to issue to the Investors unregistered warrants (the " Warrants ") to purchase 2,667,000 shares of Common Stock (the " Warrant Shares "), with each Warrant exercisable for one share of Common Stock at an exercise price of $2.12 per share. Each Warrant will be exercisable beginning six months from the date of issuance and will expire five years following the initial exercise date. The Company also issued a warrant to the Placement Agent (the " Placement Agent's Warrant "), exercisable to purchase 133,350 shares of Common Stock, representing 5% of the Shares purchased at the Closing, for an aggregate purchase price of $100.00, at an exercise price of $2.8125 per share, which is equal to 125% of the Share Offering Price. The gross proceeds from the Offering are expected to be approximately $6,000,750 before deducting placement agent fees and other offering expenses payable by the Company. The Offering is expected to close on October 24, 2024. Pursuant to the terms of the Agreement, the Company is required, among other things, to file a registration statement to register the resale of the Warrant Shares held by such Investors with the U.S. Securities and Exchange Commission (the " SEC ") within 30 days following the closing of the Private Placement. The Agreement contains customary represe

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities The information contained above in Item 1.01 relating to the Private Placement is hereby incorporated by reference into this Item 3.02. The Warrants and the Warrant Shares were offered to the Investors pursuant to an exemption from the registration requirements of the Securities Act provided under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The sale of such securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Warrants and the Warrant Shares have not been registered under the Securities Act and the Warrants and the Warrant Shares may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. -1- This Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Item7.01 Regulation FD Disclosure. On October 23, 2024, the Company issued a press release announcing the Offering. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. -2-

Forward-Looking Statements

Forward-Looking Statements Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company's expectations regarding the timing and completion of the Offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the Offering. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's prospectus supplement on Form 424B5 filed with the SEC on October 23, 2024. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Warrant. 4.2 Form of Placement Agent's Warrant Agreement (included in Exhibit 10.1). 5.1 Opinion of Fennemore Craig, P.C. 10.1* Placement Agent Agreement, dated as of October 23, 2024 by and between the Company and the Placement Agent. 23.1 Consent of Fennemore Craig, P.C. (included in Exhibit 5.1). 99.1 Press Release dated October 23, 2024. * Certain portions of this Exhibit have been omitted pursuant to Regulation S-K Item 601(a)(6) promulgated under the Exchange Act. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. -3-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 24, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer -4-

View Full Filing

View this 8-K filing on SEC EDGAR